COPENHAGEN, April 22 /PRNewswire/ --
- Consolidates the Global Rights for the Product
- TopoTarget Successfully Buys Back Full Control of Belinostat, Consolidating the Global Rights for the Product
- TopoTarget Acquires US & RoW Rights From CuraGen Corporation
- Deal Covers a Payment of USD 26 million (DKK 122.8 million), a Total of 5 Million TopoTarget Shares and a Commercial Milestone Payment
- Webcast Conference Call to be Held 2pm CET
TopoTarget A/S (OMX: TOPO) today announced that the company has successfully gained full control of belinostat so that global rights are now wholly owned by the company. Belinostat is TopoTarget's lead product in clinical development and is due to enter registration trial in the second half of this year.